{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:31:19Z","timestamp":1794274279282,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory (R\/R) B cell non-Hodgkin lymphoma after \u22652 lines of therapy. Here primary analysis of the diffuse large B cell lymphoma (DLBCL) cohort is reported. Patients received intravenous odronextamab in 21-day cycles until progression or unacceptable toxicity, with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS) risk. The primary endpoint was objective response rate (ORR). Secondary endpoints included complete response (CR) rate, duration of response, progression-free survival (PFS) and overall survival. A total of 127 patients were enrolled. At the 29.9-month efficacy follow-up, the ORR was 52.0% and CR rate was 31.5%. Median durations of response and CR were 10.2 and 17.9\u2009months, respectively. Undetectable minimal residual disease at cycle 4 day 15 was associated with PFS benefit. With a step-up of 0.7 to 4 to 20\u2009mg (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200960), CRS was the most common treatment-emergent adverse event (53.3% (grade \u22653, 1.7%)). No immune effector cell-associated neurotoxicity syndrome was reported. Infections were reported in 82\/127 (64.6%) patients (grade \u22653, 38.6%; coronavirus disease 2019, 18.1% (grade \u22653, 12.6%)). In conclusion, odronextamab showed encouraging efficacy in heavily pretreated R\/R DLBCL and generally manageable safety with supportive care. Clinical trial registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03888105\" ext-link-type=\"uri\">NCT03888105<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s43018-025-00921-6","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T06:03:19Z","timestamp":1742191399000},"page":"528-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-0466","authenticated-orcid":false,"given":"Won Seog","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Iskierka-Ja\u017cd\u017cewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Mei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran-Der","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarish","family":"Ayyappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Ufkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurriaan","family":"Brouwer-Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aafia","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ELM-2 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Ganju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Margaret","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi Laurent","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Bouabdballah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Delwail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Graf","family":"La Rosee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Hebart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Capochiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Zilioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bagnato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brociner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Skert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Battistini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Flenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Tobai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Taszner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech-Maranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Knopinska-Posluszny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wrobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Son","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Yeu","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeung-Chul","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Rok Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jimenez-Ubieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin Penedo","family":"Coello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gonzalez-Barca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Miqueleiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kuhnl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagah","family":"Elmusharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ibrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C.","family":"Villasboas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhee","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"921_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya, S. & Barta, S. K. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am. J. Hematol. 96, 617\u2013629 (2021).","journal-title":"Am. J. Hematol."},{"key":"921_CR2","doi-asserted-by":"publisher","first-page":"e390802","DOI":"10.1200\/EDBK_390802","volume":"43","author":"C Duarte","year":"2023","unstructured":"Duarte, C. & Kamdar, M. Management considerations for patients with primary refractory and early relapsed diffuse large B-cell lymphoma. Am. Soc. Clin. Oncol. Educ. Book 43, e390802 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"921_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bjh.18197","volume":"198","author":"S Harrysson","year":"2022","unstructured":"Harrysson, S. et al. Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line\u2014a population-based study of 736 patients. Br. J. Haematol. 198, 267\u2013277 (2022).","journal-title":"Br. J. Haematol."},{"key":"921_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/hematology.2022000332","volume":"2022","author":"CR Flowers","year":"2022","unstructured":"Flowers, C. R. & Odejide, O. O. Sequencing therapy in relapsed DLBCL. Hematology Am. Soc. Hematol. Educ. Program 2022, 146\u2013154 (2022).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"921_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"921_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"921_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"921_CR8","unstructured":"Highlights of Prescribing Information: BREYANZI\u00ae (U.S. Food and Drug Administration, accessed 21 January 2025); https:\/\/www.fda.gov\/media\/145711\/download"},{"key":"921_CR9","unstructured":"Highlights of Prescribing Information: KYMRIAH\u00ae (U.S. Food and Drug Administration, accessed 21 January 2025); https:\/\/www.fda.gov\/media\/107296\/download"},{"key":"921_CR10","unstructured":"Highlights of Prescribing Information: YESCARTA\u00ae (U.S. Food and Drug Administration, accessed 21 January 2025); https:\/\/www.fda.gov\/media\/108377\/download"},{"key":"921_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"921_CR12","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"921_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell, J. et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin. Pharmacol. Ther. 106, 781\u2013791 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"921_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hon.3154","volume":"41","author":"M Hutchings","year":"2023","unstructured":"Hutchings, M. The evolving therapy of DLBCL: bispecific antibodies. Hematol. Oncol. 41, 107\u2013111 (2023).","journal-title":"Hematol. Oncol."},{"key":"921_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk, N. W. C. J. & Zweegman, S. T-cell-engaging bispecific antibodies in cancer. Lancet 402, 142\u2013158 (2023).","journal-title":"Lancet"},{"key":"921_CR16","unstructured":"Highlights of Prescribing Information: COLUMVITM (U.S. Food and Drug Administration, accessed 21 January 2025); https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761309s000lbl.pdf"},{"key":"921_CR17","unstructured":"Highlights of Prescribing Information: EPKINLYTM (U.S. Food and Drug Administration, accessed 21 January 2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761324s003lbl.pdf"},{"key":"921_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep17943","volume":"5","author":"EJ Smith","year":"2015","unstructured":"Smith, E. J. et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci. Rep. 5, 17943 (2015).","journal-title":"Sci. Rep."},{"key":"921_CR19","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji, R. et al. Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 9, e327\u2013e339 (2022).","journal-title":"Lancet Haematol."},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1182\/blood-2023-181602","volume":"142","author":"JL Crombie","year":"2023","unstructured":"Crombie, J. L. et al. Odronextamab demonstrates durable complete responses in patients with diffuse large B-cell lymphoma (DLBCL) progressing after CAR-T therapy: outcomes from the ELM-1 study. Blood 142, 4461 (2023).","journal-title":"Blood"},{"key":"921_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2020-138737","volume":"136","author":"KE Smedby","year":"2020","unstructured":"Smedby, K. E. et al. Evaluation of eligibility for CAR-T cell therapy in a population-based cohort of 3550 patients with incident diffuse large B-cell lymphoma (DLBCL) in Sweden. Blood 136, 38\u201339 (2020).","journal-title":"Blood"},{"key":"921_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128295","volume":"10","author":"M\u00c1 Canales Albandea","year":"2023","unstructured":"Canales Albandea, M. \u00c1. et al. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Front. Med. (Lausanne) 10, 1128295 (2023).","journal-title":"Front. Med. (Lausanne)"},{"key":"921_CR23","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/10428194.2020.1849676","volume":"62","author":"A Di Rocco","year":"2021","unstructured":"Di Rocco, A. et al. Relapsed\/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. Leuk. Lymphoma 62, 828\u2013836 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"921_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","volume":"29","author":"MS Hoffmann","year":"2023","unstructured":"Hoffmann, M. S., Hunter, B. D., Cobb, P. W., Varela, J. C. & Munoz, J. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma. Transplant Cell. Ther. 29, 440\u2013448 (2023).","journal-title":"Transplant Cell. Ther."},{"key":"921_CR25","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/OP.22.00315","volume":"18","author":"J Mikhael","year":"2022","unstructured":"Mikhael, J., Fowler, J. & Shah, N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol. Pract. 18, 800\u2013807 (2022).","journal-title":"JCO Oncol. Pract."},{"key":"921_CR26","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood.2023020197","volume":"142","author":"D Chihara","year":"2023","unstructured":"Chihara, D. et al. Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood 142, 1047\u20131055 (2023).","journal-title":"Blood"},{"key":"921_CR27","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi, R. et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood 140, 2584\u20132593 (2022).","journal-title":"Blood"},{"key":"921_CR28","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"921_CR29","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont, C. et al. Epcoritamab, a novel, subcutaneous CD3\u00d7CD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J. Clin. Oncol. 41, 2238\u20132247 (2023).","journal-title":"J. Clin. Oncol."},{"key":"921_CR30","doi-asserted-by":"publisher","first-page":"11560","DOI":"10.1182\/blood-2022-158415","volume":"140","author":"M Zhu","year":"2022","unstructured":"Zhu, M. et al. Optimization of intravenous odronextamab step-up regimen for reducing the risk of high-grade cytokine release syndrome. Blood 140, 11560\u201311561 (2022).","journal-title":"Blood"},{"key":"921_CR31","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/blood-2023-180743","volume":"142","author":"E Iskierka-Ja\u017cd\u017cewska","year":"2023","unstructured":"Iskierka-Ja\u017cd\u017cewska, E. et al. Health-related quality of life and symptoms in patients with relapsed or refractory diffuse large B-cell lymphoma treated with odronextamab monotherapy in the phase 2 ELM-2 study. Blood 142, 4504 (2023).","journal-title":"Blood"},{"key":"921_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier, B. & Sarkozy, C. Diffuse large B-cell lymphoma: R-CHOP failure\u2014what to do? Hematology Am. Soc. Hematol. Educ. Program 2016, 366\u2013378 (2016).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"921_CR33","doi-asserted-by":"publisher","first-page":"51494","DOI":"10.18632\/oncotarget.9860","volume":"7","author":"T Melchardt","year":"2016","unstructured":"Melchardt, T. et al. Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget 7, 51494\u201351502 (2016).","journal-title":"Oncotarget"},{"key":"921_CR34","doi-asserted-by":"publisher","first-page":"e008338","DOI":"10.1136\/jitc-2023-008338","volume":"12","author":"J Brouwer-Visser","year":"2024","unstructured":"Brouwer-Visser, J. et al. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma. J. Immunother. Cancer 12, e008338 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"921_CR36","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321\u20133330 (2016).","journal-title":"Blood"},{"key":"921_CR37","doi-asserted-by":"publisher","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus, M. V. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J. Immunother. Cancer 8, e001511 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"921_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"921_CR39","unstructured":"EU Risk Management Plan for Columvi\/Glofitamab Version 1.2 (F. Hoffmann-La Roche, Ltd, accessed 21 January 2025); https:\/\/www.ema.europa.eu\/en\/documents\/rmp\/columvi-epar-risk-management-plan_en.pdf"},{"key":"921_CR40","unstructured":"EU Risk Management Plan for Epcoritamab Version 1.4 (AbbVie, Inc., accessed 21 January 2025); https:\/\/www.ema.europa.eu\/en\/documents\/rmp\/tepkinly-epar-risk-management-plan_en.pdf"},{"key":"921_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12865-022-00536-x","volume":"24","author":"C Lutz","year":"2023","unstructured":"Lutz, C. et al. Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic. BMC Immunol. 24, 2 (2023).","journal-title":"BMC Immunol."},{"key":"921_CR42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40520-019-01375-4","volume":"33","author":"D Schoevaerdts","year":"2021","unstructured":"Schoevaerdts, D., Sibille, F. X. & Gavazzi, G. Infections in the older population: what do we know?. Aging. Clin. Exp. Res. 33, 689\u2013701 (2021).","journal-title":"Aging. Clin. Exp. Res."},{"key":"921_CR43","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","volume":"35","author":"TM Kim","year":"2024","unstructured":"Kim, T. M. et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann. Oncol. 35, 1039\u20131047 (2024).","journal-title":"Ann. Oncol."},{"key":"921_CR44","unstructured":"Clinical Practice Guidelines in Oncology for Prevention and Treatment of Cancer-Related Infections Version 3 (National Comprehensive Cancer Network, accessed 17 January 2025); https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf"},{"key":"921_CR45","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz, R. A. et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J. Clin. Oncol. 36, 3043\u20133054 (2018).","journal-title":"J. Clin. Oncol."},{"key":"921_CR46","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky, J. et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann. Oncol. 27, v111\u2013v118 (2016).","journal-title":"Ann. Oncol."},{"key":"921_CR47","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F. et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332 (2010).","journal-title":"BMJ"},{"key":"921_CR48","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"921_CR49","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz, D. M. et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J. Clin. Oncol. 36, 2845\u20132853 (2018).","journal-title":"J. Clin. Oncol."},{"key":"921_CR50","doi-asserted-by":"publisher","first-page":"9257","DOI":"10.1182\/blood-2022-162814","volume":"140","author":"RP Stokowski","year":"2022","unstructured":"Stokowski, R. P. et al. Detection of early molecular response (EMR) and minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using a validated next generation sequencing (NGS) assay for the detection of tumor variants in circulating tumor (ct)DNA. Blood 140, 9257\u20139258 (2022).","journal-title":"Blood"},{"key":"921_CR51","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."}],"updated-by":[{"DOI":"10.1038\/s43018-025-00967-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000}}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00921-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00921-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00921-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:02:43Z","timestamp":1744858963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00921-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-00921-6","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s43018-025-00967-6","URL":"https:\/\/doi.org\/10.1038\/s43018-025-00967-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.S.K. reports research funding from BeiGene, Boryung, Donga, Kyowa-Kirin, Roche and Sanofi. T.M.K. reports honoraria from Amgen, AstraZeneca, IMBDx, Janssen, MedImmune and Takeda, trial research funding to institution from AstraZeneca, consultancy for AstraZeneca, Boryung, F.Hoffmann-La Roche, Janssen, MedImmune, Novartis, Regeneron Pharmaceuticals, Inc., Roche, Samsung Bioepis, Takeda and Yuhan, speaker bureau fees for IMBDx, Janssen and Takeda, membership on an entity\u2019s board of directors or advisory committees for BeiGene, Janssen, Novartis, Regeneron Pharmaceuticals, Inc., Roche and Takeda and an uncompensated relationship with AstraZeneca, Boryung, MedImmune, Novartis and Roche. I.J. reports consultancy for Amgen, AstraZeneca, Kyowa-Kirin, Novartis, Pfizer, Sobi and Takeda, research funding from Amgen, AstraZeneca, BeiGene, Incyte, Janssen, Regeneron Pharmaceuticals, Inc., Sobi and Takeda and honoraria fees from AstraZeneca, Incyte, Janssen, Novartis, Pfizer, Sobi and Takeda. E.I.-J. reports consultancy for AbbVie and AstraZeneca and honoraria from AbbVie, AstraZeneca, Janssen and Novartis. L.M.P. reports research funding from Regeneron Pharmaceuticals, Inc. B.T. reports honoraria from AbbVie, Gilead, Incyte and Kite. C.C. reports honoraria from Gilead, Novartis, Regeneron Pharmaceuticals, Inc. and Takeda, consultancy for BMS, Regeneron Pharmaceuticals, Inc. and Takeda and membership on an entity\u2019s board of directors or advisory committees for Regeneron Pharmaceuticals, Inc. and Takeda. Sa.A. reports membership on an entity\u2019s board of directors or advisory committee for AbbVie, AstraZeneca, BeiGene, Fate Therapeutics and Regeneron Pharmaceuticals, Inc., consultancy for ADC Therapeutics and AstraZeneca and speaker bureau fees from BeiGene and Genentech. J. Cai, M.U., S.S., J.B.-V., A.C., H.M. and S. Ambati hold stock or stock options for and are employees of Regeneron Pharmaceuticals, Inc. J.W. reports consultancy for AbbVie, Gilead, Novartis, Roche, Takeda and MSD, research or clinical trial funding from GSK, Novartis and Roche and honoraria from AbbVie, Amgen, Gilead, GSK, Novartis, Roche and Takeda. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}